View Future GrowthRobertet 과거 순이익 실적과거 기준 점검 5/6Robertet은 연평균 11%의 비율로 수입이 증가해 온 반면, Chemicals 산업은 수입이 3% 증가했습니다. 매출은 연평균 9%의 비율로 증가했습니다. Robertet의 자기자본이익률은 17.3%이고 순이익률은 12.3%입니다.핵심 정보11.02%순이익 성장률13.05%주당순이익(EPS) 성장률Chemicals 산업 성장률4.35%매출 성장률8.97%자기자본이익률17.28%순이익률12.26%다음 순이익 업데이트17 Sep 2026최근 과거 실적 업데이트Reported Earnings • Apr 17Full year 2025 earnings releasedFull year 2025 results: Revenue: €849.8m (up 5.2% from FY 2024). Net income: €103.4m (up 15% from FY 2024). Profit margin: 12% (up from 11% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 7.0% decline forecast for the Chemicals industry in the United Kingdom.공시 • Feb 12Robertet SA to Report First Half, 2026 Final Results on Sep 21, 2026Robertet SA announced that they will report first half, 2026 final results on Sep 21, 2026공시 • Jan 02+ 2 more updatesRobertet SA to Report Fiscal Year 2025 Results on Apr 09, 2026Robertet SA announced that they will report fiscal year 2025 results at 9:00 AM, Central European Standard Time on Apr 09, 2026공시 • Sep 12Robertet SA to Report First Half, 2025 Final Results on Sep 18, 2025Robertet SA announced that they will report first half, 2025 final results on Sep 18, 2025공시 • Jul 25Robertet SA to Report First Half, 2025 Results on Sep 11, 2025Robertet SA announced that they will report first half, 2025 results on Sep 11, 2025Reported Earnings • Sep 27First half 2024 earnings released: EPS: €24.71 (vs €19.14 in 1H 2023)First half 2024 results: EPS: €24.71 (up from €19.14 in 1H 2023). Revenue: €414.6m (up 10% from 1H 2023). Net income: €51.7m (up 29% from 1H 2023). Profit margin: 13% (up from 11% in 1H 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 5.5% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.모든 업데이트 보기Recent updatesDeclared Dividend • May 04Dividend increased to €12.00Dividend of €12.00 is 20% higher than last year. Ex-date: 29th June 2026 Payment date: 1st July 2026 Dividend yield will be 1.5%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is well covered by both earnings (25% earnings payout ratio) and cash flows (38% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 25% over the next 3 years, which should provide support to the dividend and adequate earnings cover.공시 • Apr 28Robertet SA, Annual General Meeting, Jun 03, 2026Robertet SA, Annual General Meeting, Jun 03, 2026. Location: 48 avenue jean maubert, grasse FranceReported Earnings • Apr 17Full year 2025 earnings releasedFull year 2025 results: Revenue: €849.8m (up 5.2% from FY 2024). Net income: €103.4m (up 15% from FY 2024). Profit margin: 12% (up from 11% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 7.0% decline forecast for the Chemicals industry in the United Kingdom.공시 • Apr 11Robertet SA Proposes Dividend for the Year 2025Robertet SA announced the Annual General Meeting will be held on June 3, 2026 and the shareholders will be invited to approve a dividend payment of €12 per share, up 20% on the previous year owing to Robertet's strong results in 2025.공시 • Feb 12Robertet SA to Report First Half, 2026 Final Results on Sep 21, 2026Robertet SA announced that they will report first half, 2026 final results on Sep 21, 2026Board Change • Jan 16Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 6 non-independent directors. Independent Director Lucie Maurel-Aubert was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Jan 02+ 2 more updatesRobertet SA to Report Fiscal Year 2025 Results on Apr 09, 2026Robertet SA announced that they will report fiscal year 2025 results at 9:00 AM, Central European Standard Time on Apr 09, 2026공시 • Sep 12Robertet SA to Report First Half, 2025 Final Results on Sep 18, 2025Robertet SA announced that they will report first half, 2025 final results on Sep 18, 2025공시 • Jul 25Robertet SA to Report First Half, 2025 Results on Sep 11, 2025Robertet SA announced that they will report first half, 2025 results on Sep 11, 2025Upcoming Dividend • Jun 20Upcoming dividend of €10.00 per shareEligible shareholders must have bought the stock before 27 June 2025. Payment date: 01 July 2025. Payout ratio is a comfortable 23% and this is well supported by cash flows. Trailing yield: 1.2%. Lower than top quartile of British dividend payers (5.6%). Lower than average of industry peers (4.1%).공시 • Apr 29Robertet SA, Annual General Meeting, Jun 04, 2025Robertet SA, Annual General Meeting, Jun 04, 2025. Location: 48 avenue jean maubert, grasse FranceDeclared Dividend • Apr 28Dividend increased to €10.00Dividend of €10.00 is 18% higher than last year. Ex-date: 27th June 2025 Payment date: 1st July 2025 Dividend yield will be 1.2%, which is lower than the industry average of 3.0%.공시 • Nov 06Robertet SA (ENXTPA:RBT) agreed to acquire Phasex Corporation.Robertet SA (ENXTPA:RBT) agreed to acquire Phasex Corporation on November 4, 2024.Reported Earnings • Sep 27First half 2024 earnings released: EPS: €24.71 (vs €19.14 in 1H 2023)First half 2024 results: EPS: €24.71 (up from €19.14 in 1H 2023). Revenue: €414.6m (up 10% from 1H 2023). Net income: €51.7m (up 29% from 1H 2023). Profit margin: 13% (up from 11% in 1H 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 5.5% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.Board Change • Jun 06High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Lucie Maurel-Aubert was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 22Full year 2023 earnings released: EPS: €35.71 (vs €32.85 in FY 2022)Full year 2023 results: EPS: €35.71. Revenue: €735.6m (up 4.6% from FY 2022). Net income: €74.6m (down 1.9% from FY 2022). Profit margin: 10% (in line with FY 2022). Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 2.4% decline forecast for the Chemicals industry in the United Kingdom.New Risk • Apr 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. This is currently the only risk that has been identified for the company.공시 • Apr 12+ 2 more updatesRobertet SA to Report First Half, 2024 Results on Sep 23, 2024Robertet SA announced that they will report first half, 2024 results on Sep 23, 2024Buy Or Sell Opportunity • Apr 09Now 20% undervaluedOver the last 90 days, the stock has risen 1.8% to €807. The fair value is estimated to be €1,011, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 15%. For the next 3 years, revenue is forecast to grow by 5.1% per annum. Earnings are also forecast to grow by 12% per annum over the same time period.Buy Or Sell Opportunity • Feb 21Now 22% undervaluedOver the last 90 days, the stock has risen 4.5% to €794. The fair value is estimated to be €1,024, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 15%. For the next 3 years, revenue is forecast to grow by 5.1% per annum. Earnings are also forecast to grow by 12% per annum over the same time period.Buy Or Sell Opportunity • Feb 21Now 22% undervaluedOver the last 90 days, the stock has risen 4.8% to €794. The fair value is estimated to be €1,022, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 15%. For the next 3 years, revenue is forecast to grow by 5.1% per annum. Earnings are also forecast to grow by 12% per annum over the same time period.Reported Earnings • Oct 05First half 2023 earnings released: EPS: €19.13 (vs €19.49 in 1H 2022)First half 2023 results: EPS: €19.13 (down from €19.49 in 1H 2022). Revenue: €376.4m (up 4.9% from 1H 2022). Net income: €39.9m (down 11% from 1H 2022). Profit margin: 11% (down from 13% in 1H 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 5.1% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.Upcoming Dividend • Jun 22Upcoming dividend of €8.50 per share at 1.0% yieldEligible shareholders must have bought the stock before 29 June 2023. Payment date: 03 July 2023. Payout ratio is a comfortable 26% and the cash payout ratio is 77%. Trailing yield: 1.0%. Lower than top quartile of British dividend payers (5.9%). Lower than average of industry peers (2.8%).Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 8 experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). Director Elie Vannier was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • May 01Full year 2021 earnings releasedFull year 2021 results: Revenue: €608.8m (up 13% from FY 2020). Net income: €71.7m (up 42% from FY 2020). Profit margin: 12% (up from 9.4% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 11% compared to a 16% decline forecast for the industry in the United Kingdom.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Oct 01First half 2021 earnings released: EPS €16.47 (vs €13.03 in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: €297.6m (up 6.2% from 1H 2020). Net income: €38.1m (up 27% from 1H 2020). Profit margin: 13% (up from 11% in 1H 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 20% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • May 05Full year 2020 earnings released: EPS €21.88 (vs €22.96 in FY 2019)The company reported a poor full year result with weaker earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: €538.3m (down 2.9% from FY 2019). Net income: €50.6m (down 4.7% from FY 2019). Profit margin: 9.4% (in line with FY 2019). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 27% per year, which means it is tracking significantly ahead of earnings growth.Is New 90 Day High Low • Jan 29New 90-day high: €955The company is up 3.0% from its price of €923 on 30 October 2020. The British market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 20% over the same period.Is New 90 Day High Low • Dec 11New 90-day low: €546The company is down 45% from its price of €996 on 11 September 2020. The British market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 5.0% over the same period.Valuation Update With 7 Day Price Move • Dec 11Investor sentiment deteriorated over the past weekAfter last week's 38% share price decline to €546, the stock is trading at a trailing P/E ratio of 36.9x, down from the previous P/E ratio of 59.8x. This compares to an average P/E of 40x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years are 40%.Valuation Update With 7 Day Price Move • Dec 10Market pulls back on stock over the past weekAfter last week's 39% share price decline to €546, the stock is trading at a trailing P/E ratio of 36.9x, down from the previous P/E ratio of 60.7x. This compares to an average P/E of 40x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years are 39%.Valuation Update With 7 Day Price Move • Dec 07Market pulls back on stock over the past weekAfter last week's 40% share price decline to €546, the stock is trading at a trailing P/E ratio of 38.3x, down from the previous P/E ratio of 63.4x. This compares to an average P/E of 39x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years are 39%.Valuation Update With 7 Day Price Move • Dec 03Market pulls back on stock over the past weekAfter last week's 39% share price decline to €546, the stock is trading at a trailing P/E ratio of 38.7x, down from the previous P/E ratio of 63.2x. This compares to an average P/E of 39x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years are 39%.Valuation Update With 7 Day Price Move • Nov 30Market pulls back on stock over the past weekAfter last week's 39% share price decline to €546, the stock is trading at a trailing P/E ratio of 38.7x, down from the previous P/E ratio of 63.8x. This compares to an average P/E of 38x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years are 39%.Valuation Update With 7 Day Price Move • Nov 27Market pulls back on stock over the past weekAfter last week's 40% share price decline to €546, the stock is trading at a trailing P/E ratio of 38.7x, down from the previous P/E ratio of 64.1x. This compares to an average P/E of 37x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years are 39%.Valuation Update With 7 Day Price Move • Nov 24Market pulls back on stock over the past weekAfter last week's 42% share price decline to €546, the stock is trading at a trailing P/E ratio of 38.5x, down from the previous P/E ratio of 66.8x. This compares to an average P/E of 40x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years are 39%.Is New 90 Day High Low • Nov 20New 90-day low: €546The company is down 39% from its price of €897 on 21 August 2020. The British market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 8.0% over the same period.Valuation Update With 7 Day Price Move • Nov 20Market pulls back on stock over the past weekAfter last week's 42% share price decline to €546, the stock is trading at a trailing P/E ratio of 38.5x, down from the previous P/E ratio of 66.8x. This compares to an average P/E of 39x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years are 39%.Is New 90 Day High Low • Oct 12New 90-day high: €1,036The company is up 8.0% from its price of €958 on 13 July 2020. The British market is down 1.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 10.0% over the same period.Reported Earnings • Oct 02First half earnings releasedOver the last 12 months the company has reported total profits of €53.7m, largely unchanged from the prior year. Total revenue was €547.4m over the last 12 months, up 1.0% from the prior year.매출 및 비용 세부 내역Robertet가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이LSE:0NZN 매출, 비용 및 순이익 (EUR Millions)날짜매출순이익일반관리비연구개발비31 Dec 25844103323030 Sep 25842100318030 Jun 2583997313031 Mar 2582493304031 Dec 2480890295030 Sep 2478388288030 Jun 2475986282031 Mar 2474080274031 Dec 2372175266030 Sep 2372173260030 Jun 2372171255031 Mar 2371273249031 Dec 2270376244030 Sep 2268577239030 Jun 2266779234031 Mar 2263775224031 Dec 2160672214030 Sep 2158165204030 Jun 2155659193031 Mar 2154755191031 Dec 2053851189030 Sep 2054352191030 Jun 2054754193031 Mar 2055153195031 Dec 1955453197030 Sep 1954853195030 Jun 1954254192031 Mar 1953353191031 Dec 1852552190030 Sep 1852051189030 Jun 1851651188031 Mar 1851050187031 Dec 1750449187030 Sep 1749647186030 Jun 1748845186031 Mar 1747843183031 Dec 1646842181030 Sep 1646340179030 Jun 1645739177031 Mar 1644637174031 Dec 1543536171030 Sep 1542334168030 Jun 15410331650양질의 수익: 0NZN는 고품질 수익을 보유하고 있습니다.이익 마진 증가: 0NZN의 현재 순 이익률 (12.3%)은 지난해 (11.2%)보다 높습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 0NZN의 수익은 지난 5년 동안 연평균 11% 증가했습니다.성장 가속화: 지난 1년간 0NZN 의 수익 증가율(14.8%)은 연간 평균(11%)을 초과합니다.수익 대 산업: 0NZN의 지난 1년 수익 증가율(14.8%)은 Chemicals 업계의 -59.9%를 상회했습니다.자기자본이익률높은 ROE: 0NZN의 자본 수익률(17.3%)은 낮음으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YMaterials 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/23 03:58종가2026/05/22 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Robertet SA는 15명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Fraser DonlonBerenbergMarie-Line FortBernsteinNicola TangBNP Paribas12명의 분석가 더 보기
Reported Earnings • Apr 17Full year 2025 earnings releasedFull year 2025 results: Revenue: €849.8m (up 5.2% from FY 2024). Net income: €103.4m (up 15% from FY 2024). Profit margin: 12% (up from 11% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 7.0% decline forecast for the Chemicals industry in the United Kingdom.
공시 • Feb 12Robertet SA to Report First Half, 2026 Final Results on Sep 21, 2026Robertet SA announced that they will report first half, 2026 final results on Sep 21, 2026
공시 • Jan 02+ 2 more updatesRobertet SA to Report Fiscal Year 2025 Results on Apr 09, 2026Robertet SA announced that they will report fiscal year 2025 results at 9:00 AM, Central European Standard Time on Apr 09, 2026
공시 • Sep 12Robertet SA to Report First Half, 2025 Final Results on Sep 18, 2025Robertet SA announced that they will report first half, 2025 final results on Sep 18, 2025
공시 • Jul 25Robertet SA to Report First Half, 2025 Results on Sep 11, 2025Robertet SA announced that they will report first half, 2025 results on Sep 11, 2025
Reported Earnings • Sep 27First half 2024 earnings released: EPS: €24.71 (vs €19.14 in 1H 2023)First half 2024 results: EPS: €24.71 (up from €19.14 in 1H 2023). Revenue: €414.6m (up 10% from 1H 2023). Net income: €51.7m (up 29% from 1H 2023). Profit margin: 13% (up from 11% in 1H 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 5.5% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
Declared Dividend • May 04Dividend increased to €12.00Dividend of €12.00 is 20% higher than last year. Ex-date: 29th June 2026 Payment date: 1st July 2026 Dividend yield will be 1.5%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is well covered by both earnings (25% earnings payout ratio) and cash flows (38% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 25% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
공시 • Apr 28Robertet SA, Annual General Meeting, Jun 03, 2026Robertet SA, Annual General Meeting, Jun 03, 2026. Location: 48 avenue jean maubert, grasse France
Reported Earnings • Apr 17Full year 2025 earnings releasedFull year 2025 results: Revenue: €849.8m (up 5.2% from FY 2024). Net income: €103.4m (up 15% from FY 2024). Profit margin: 12% (up from 11% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 7.0% decline forecast for the Chemicals industry in the United Kingdom.
공시 • Apr 11Robertet SA Proposes Dividend for the Year 2025Robertet SA announced the Annual General Meeting will be held on June 3, 2026 and the shareholders will be invited to approve a dividend payment of €12 per share, up 20% on the previous year owing to Robertet's strong results in 2025.
공시 • Feb 12Robertet SA to Report First Half, 2026 Final Results on Sep 21, 2026Robertet SA announced that they will report first half, 2026 final results on Sep 21, 2026
Board Change • Jan 16Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 6 non-independent directors. Independent Director Lucie Maurel-Aubert was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Jan 02+ 2 more updatesRobertet SA to Report Fiscal Year 2025 Results on Apr 09, 2026Robertet SA announced that they will report fiscal year 2025 results at 9:00 AM, Central European Standard Time on Apr 09, 2026
공시 • Sep 12Robertet SA to Report First Half, 2025 Final Results on Sep 18, 2025Robertet SA announced that they will report first half, 2025 final results on Sep 18, 2025
공시 • Jul 25Robertet SA to Report First Half, 2025 Results on Sep 11, 2025Robertet SA announced that they will report first half, 2025 results on Sep 11, 2025
Upcoming Dividend • Jun 20Upcoming dividend of €10.00 per shareEligible shareholders must have bought the stock before 27 June 2025. Payment date: 01 July 2025. Payout ratio is a comfortable 23% and this is well supported by cash flows. Trailing yield: 1.2%. Lower than top quartile of British dividend payers (5.6%). Lower than average of industry peers (4.1%).
공시 • Apr 29Robertet SA, Annual General Meeting, Jun 04, 2025Robertet SA, Annual General Meeting, Jun 04, 2025. Location: 48 avenue jean maubert, grasse France
Declared Dividend • Apr 28Dividend increased to €10.00Dividend of €10.00 is 18% higher than last year. Ex-date: 27th June 2025 Payment date: 1st July 2025 Dividend yield will be 1.2%, which is lower than the industry average of 3.0%.
공시 • Nov 06Robertet SA (ENXTPA:RBT) agreed to acquire Phasex Corporation.Robertet SA (ENXTPA:RBT) agreed to acquire Phasex Corporation on November 4, 2024.
Reported Earnings • Sep 27First half 2024 earnings released: EPS: €24.71 (vs €19.14 in 1H 2023)First half 2024 results: EPS: €24.71 (up from €19.14 in 1H 2023). Revenue: €414.6m (up 10% from 1H 2023). Net income: €51.7m (up 29% from 1H 2023). Profit margin: 13% (up from 11% in 1H 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 5.5% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
Board Change • Jun 06High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Lucie Maurel-Aubert was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 22Full year 2023 earnings released: EPS: €35.71 (vs €32.85 in FY 2022)Full year 2023 results: EPS: €35.71. Revenue: €735.6m (up 4.6% from FY 2022). Net income: €74.6m (down 1.9% from FY 2022). Profit margin: 10% (in line with FY 2022). Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 2.4% decline forecast for the Chemicals industry in the United Kingdom.
New Risk • Apr 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. This is currently the only risk that has been identified for the company.
공시 • Apr 12+ 2 more updatesRobertet SA to Report First Half, 2024 Results on Sep 23, 2024Robertet SA announced that they will report first half, 2024 results on Sep 23, 2024
Buy Or Sell Opportunity • Apr 09Now 20% undervaluedOver the last 90 days, the stock has risen 1.8% to €807. The fair value is estimated to be €1,011, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 15%. For the next 3 years, revenue is forecast to grow by 5.1% per annum. Earnings are also forecast to grow by 12% per annum over the same time period.
Buy Or Sell Opportunity • Feb 21Now 22% undervaluedOver the last 90 days, the stock has risen 4.5% to €794. The fair value is estimated to be €1,024, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 15%. For the next 3 years, revenue is forecast to grow by 5.1% per annum. Earnings are also forecast to grow by 12% per annum over the same time period.
Buy Or Sell Opportunity • Feb 21Now 22% undervaluedOver the last 90 days, the stock has risen 4.8% to €794. The fair value is estimated to be €1,022, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 15%. For the next 3 years, revenue is forecast to grow by 5.1% per annum. Earnings are also forecast to grow by 12% per annum over the same time period.
Reported Earnings • Oct 05First half 2023 earnings released: EPS: €19.13 (vs €19.49 in 1H 2022)First half 2023 results: EPS: €19.13 (down from €19.49 in 1H 2022). Revenue: €376.4m (up 4.9% from 1H 2022). Net income: €39.9m (down 11% from 1H 2022). Profit margin: 11% (down from 13% in 1H 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 5.1% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
Upcoming Dividend • Jun 22Upcoming dividend of €8.50 per share at 1.0% yieldEligible shareholders must have bought the stock before 29 June 2023. Payment date: 03 July 2023. Payout ratio is a comfortable 26% and the cash payout ratio is 77%. Trailing yield: 1.0%. Lower than top quartile of British dividend payers (5.9%). Lower than average of industry peers (2.8%).
Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 8 experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). Director Elie Vannier was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • May 01Full year 2021 earnings releasedFull year 2021 results: Revenue: €608.8m (up 13% from FY 2020). Net income: €71.7m (up 42% from FY 2020). Profit margin: 12% (up from 9.4% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 11% compared to a 16% decline forecast for the industry in the United Kingdom.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Oct 01First half 2021 earnings released: EPS €16.47 (vs €13.03 in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: €297.6m (up 6.2% from 1H 2020). Net income: €38.1m (up 27% from 1H 2020). Profit margin: 13% (up from 11% in 1H 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 20% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • May 05Full year 2020 earnings released: EPS €21.88 (vs €22.96 in FY 2019)The company reported a poor full year result with weaker earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: €538.3m (down 2.9% from FY 2019). Net income: €50.6m (down 4.7% from FY 2019). Profit margin: 9.4% (in line with FY 2019). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 27% per year, which means it is tracking significantly ahead of earnings growth.
Is New 90 Day High Low • Jan 29New 90-day high: €955The company is up 3.0% from its price of €923 on 30 October 2020. The British market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 20% over the same period.
Is New 90 Day High Low • Dec 11New 90-day low: €546The company is down 45% from its price of €996 on 11 September 2020. The British market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 5.0% over the same period.
Valuation Update With 7 Day Price Move • Dec 11Investor sentiment deteriorated over the past weekAfter last week's 38% share price decline to €546, the stock is trading at a trailing P/E ratio of 36.9x, down from the previous P/E ratio of 59.8x. This compares to an average P/E of 40x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years are 40%.
Valuation Update With 7 Day Price Move • Dec 10Market pulls back on stock over the past weekAfter last week's 39% share price decline to €546, the stock is trading at a trailing P/E ratio of 36.9x, down from the previous P/E ratio of 60.7x. This compares to an average P/E of 40x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years are 39%.
Valuation Update With 7 Day Price Move • Dec 07Market pulls back on stock over the past weekAfter last week's 40% share price decline to €546, the stock is trading at a trailing P/E ratio of 38.3x, down from the previous P/E ratio of 63.4x. This compares to an average P/E of 39x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years are 39%.
Valuation Update With 7 Day Price Move • Dec 03Market pulls back on stock over the past weekAfter last week's 39% share price decline to €546, the stock is trading at a trailing P/E ratio of 38.7x, down from the previous P/E ratio of 63.2x. This compares to an average P/E of 39x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years are 39%.
Valuation Update With 7 Day Price Move • Nov 30Market pulls back on stock over the past weekAfter last week's 39% share price decline to €546, the stock is trading at a trailing P/E ratio of 38.7x, down from the previous P/E ratio of 63.8x. This compares to an average P/E of 38x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years are 39%.
Valuation Update With 7 Day Price Move • Nov 27Market pulls back on stock over the past weekAfter last week's 40% share price decline to €546, the stock is trading at a trailing P/E ratio of 38.7x, down from the previous P/E ratio of 64.1x. This compares to an average P/E of 37x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years are 39%.
Valuation Update With 7 Day Price Move • Nov 24Market pulls back on stock over the past weekAfter last week's 42% share price decline to €546, the stock is trading at a trailing P/E ratio of 38.5x, down from the previous P/E ratio of 66.8x. This compares to an average P/E of 40x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years are 39%.
Is New 90 Day High Low • Nov 20New 90-day low: €546The company is down 39% from its price of €897 on 21 August 2020. The British market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 8.0% over the same period.
Valuation Update With 7 Day Price Move • Nov 20Market pulls back on stock over the past weekAfter last week's 42% share price decline to €546, the stock is trading at a trailing P/E ratio of 38.5x, down from the previous P/E ratio of 66.8x. This compares to an average P/E of 39x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years are 39%.
Is New 90 Day High Low • Oct 12New 90-day high: €1,036The company is up 8.0% from its price of €958 on 13 July 2020. The British market is down 1.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 10.0% over the same period.
Reported Earnings • Oct 02First half earnings releasedOver the last 12 months the company has reported total profits of €53.7m, largely unchanged from the prior year. Total revenue was €547.4m over the last 12 months, up 1.0% from the prior year.